To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
AVICINE was developed by AVI BioPharma Inc. It is a cancer vaccine which was created to cause an immune reaction to the tumor associated antigen, human chorionic gonadotropin (hCG).
Additional recommended knowledge
This vaccine will be designed to work by actively stimulating immunization amongst tumor cells, or tumor associated antigens. These can be the keys to unlocking the cancer cells, making way for the therapeutic values of AVICINE.
Research behind the drug
This particular vaccine is a synthesized formulation of peptides developed to create an unstable environment for the hCG-producing cancer cells. By joining them together with diphtheria toxoids, the AVICINE peptide formulation is able to cause a specific immune response to hCG which won’t interfere with related glycoprotein hormones.
Common elements between pregnancy and cancer
During pregnancy, women naturally generate the hCG hormone, leading scientists to believe it stimulates growth and protects the developing fetus from auto-immune attack, therefore making the pregnancy successful. Cancer cells are believed to produce hCG for the same reasons. In both Cancer and Pregnancy hCG :
An anti-hCG vaccine would result in an immune attack on tumor cells, as well as prevent them from benefiting from hCG production.
AVICINE has been shown to be effective in blocking fertility, suggesting that it should also work in fighting cancer. These studies also note that the drug will help in patient survival.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "AVICINE". A list of authors is available in Wikipedia.|